Genmab — Januar 2021
-
Det er jo altid en "hvem blinker først konkurrence". Nogle gange eer der ingen der blinker og sagen køre helt til ende. Andre gange blinker den ene part og står pludselig ikke SÅ stejlt på sine krav længere
-
New A Study of Teclistamab With Other Anticancer Therapies in Participants With Multiple Myeloma
https://clinicaltrials.gov/ct2/show/NCT04722146 -
6 Studies already now for teclistamab https://clinicaltrials.gov/ct2/results?cond=&term=teclistamab&cntry=&state=&city=&dist=
-
God morgen.
-
Asien: Et hav af rødt på tværs af asiatiske markeder. https://www.proinvestor.com/investornyt/671434/asien-et-hav-af-rodt-pa-tvaers-af-asiatiske-markeder
-
Tirsdagens aviser med Falck, Mærsk og ATP
https://www.proinvestor.com/investornyt/671433/tirsdagens-aviser-med-falck-maersk-og-atp -
Ses vi? Tilmelding til Proinvestors webinar med Bactiquant i aften kl. 18 på link. https://bactiquant.com/investors
-
Kesimpta (ofatumumab, formerly OMB157) (USD 15 million) was launched in the US following FDA approval in August. To initiate access, we are providing Kesimpta free of charge to US patients who are eligible for reimbursement until they are covered by their insurance. Kesimpta is a targeted B-cell therapy that can deliver sustained high efficacy, with a favorable safety profile and the flexibility of an at home self-administration for a broadpopulation of RMS patients. We have seen a promising
st
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind